IRCT20080901001165N40已完成3 期
Evaluation of Therapeutic and safety of clemastine fumarate in symptoms and quality of life in secondry Relapsing MS patients
Bagheiat-allah University of Medical Sciences0 个研究点目标入组 120 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 50 years（—）
- 性别
- All
入选标准
- •inclusion criteria : To sign the consent form knowingly. At the same time,not in another clinical study. The patient is between 18-50 years old. only have a secondery recurrent MS.
排除标准
- •The patient is pregnant
研究者
相似试验
尚未招募
2 期
Evaluation of Clemastine effects in CTS pateintsCarpal tunnel syndromeIRCT20190428043404N2Iran University of Medical Sciences20
尚未招募
不适用
This study will investigate the anticancer effect and treatment-related safety when focused ultrasound stimuli is given for the pancreatic cancer in patients with unresectable pancreatic cancer who need chemotherapy in a prospective mannerNeoplasmsKCT0006302Seoul National University Hospital60
招募中
2 期
A clinical study to evaluate the comparative efficacy of three Unani drugs in the treatment of Hepatitis B carriersCTRI/2018/06/014642DG Central Council for Research in Unani Medicine
进行中（未招募）
1 期
Clemastine fumarate as remyelinating treatment in internuclear ophthalmoparesis and multiple sclerosisCTIS2024-513099-17-00Amsterdam UMC Stichting80
招募中
3 期
Clemastine fumarate as remyelinating treatment in internuclear ophthalmoparesis and multiple sclerosisMultiple sclerosis (MS)internuclear ophthalmoparesis (eye movement disorder)1003006110012303NL-OMON52129Amsterdam UMC80